Business Wire

INSTITUTO-COORDENADAS

23.6.2020 18:13:05 CEST | Business Wire | Press release

Share
Barcelona Stands out in European Research Into Fighting Covid-19

In the socioeconomic recovery of Europe’s main cities following the effects of the Covid-19 pandemic, a commitment to healthcare, innovation and medical research is a key element. In that regard, Barcelona and the surrounding area play a European leadership role, uniting a powerful healthcare field with a high quality scientific research network. And according to the initial conclusions of a study by Instituto Coordenadas, the city’s response to Covid-19 is an example of public-private partnership.

The response of the healthcare sector, ensuring Barcelona is a safe city, combines with the Catalan capital’s research efforts over several decades and its strength in recruiting talent for innovation and research in biotechnology and health. The city’s hospital network, for instance, has made great strides in both medicine and research during the crisis. Some of the main achievements in that regard include the work of Hospital Clínic, and its partnership with the US-based MIT research team in particular, and the Vall d’Hebron University Hospital, which has been congratulated by the World Health Organization (WHO) for managing the fight against the pandemic. Another example of Barcelona’s dominant position lies in the work of the SciTech DiploHub, an initiative that has succeeded in bringing together the field of international scientific diplomacy.

Barcelona’s public-private scientific ecosystem has also been at work during the Covid-19 threat, with around 20 initiatives placing Catalonia’s capital at the forefront in the fight against the pandemic. Examples go from top level clinical trials, such as the one carried out by Germans Trias i Pujol Research Institute (IGTP) to stop those with the virus spreading it further, to IQS’s efforts to find an inhibitor for attacking one of the receptors of Covid-19. Most recently, the expertise of three doctors from Barcelona’s ISGlobal played a key role in redressing the errors relating to the effectiveness of hydroxychloroquine as regards Covid-19, and there is also the example of the work being carried out into new treatments for eliminating cytokine storms.

Another development that has put Barcelona on the front line has been the global partnership between the city’s six cutting-edge science centres, 110 pharmaceutical companies – with their long-standing relationship with the city – and biotech businesses and start-ups based at the Barcelona Science Park (PCB). The aim of the alliance is to secure an effective antiretroviral drug for fighting Covid-19, vaccines and more effective rapid diagnostic tests.

PCB, with its 2,800 professionals, was Spain’s first science park and is home to IRB Barcelona, which is one of the research centres selected by the European Union to identify an effective vaccine, new treatments and better rapid diagnostic tests. In fact, of the 17 projects selected in Europe, five come from Barcelona and the surrounding area.

The fight against the virus has seen the whole of the local research network entering into partnership. For instance, the Barcelona Supercomputing Center (BSC) has made its Mare Nostrum supercomputer available to researchers so they can fight the pandemic using artificial intelligence and bioinformatics.

In short, this array of alliances has put Barcelona in a position of excellence on the European map of efforts to fight Covid-19.

ABOUT INSTITUTO COORDENADAS DE GOBERNANZA Y ECONOMIA APLICADA

The institute develops thought and undertakes research into the interaction between governance and applied economics in order to make constructive and decisive progress in three fundamental issues: social wellbeing, economic progress and environmental sustainability. This takes place in a context of development and evolution, unprecedented since the end of the 18th century and the beginning of the 19th century with the industrial revolution. Faithful to its founding principles of independence, non-partisanship and plurality, the institute is a proactive leader of the fusion between the essence and innovation of economic liberalisation as the best model for tackling the challenge of the present and the future in Spain, Europe and the world.

Further information: www.institutocoordenadas.com

NOTE: The information contained in this press release is a public interest summary from reports and studies based on analysis and research; expert working groups and sessions; and/or production of scientific articles by Instituto Coordenadas de Gobernanza y Economía Aplicada. The original and complete documents are for internal use and are the sole property of Instituto Coordenadas de Gobernanza y Economía Aplicada.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

VELOCIFERO Takes Action Against Counterfeiting in China13.11.2026 17:32:00 CET | Press release

White s.r.o., exclusive owner of the VELOCIFERO brand, takes action in China to protect its intellectual property rights. Initial measures in Chongqing and Taizhou have already resulted in the seizure of vehicles alleged to be counterfeit. VELOCIFERO is taking action against counterfeiting in China. White s.r.o., the exclusive owner of the VELOCIFERO brand and its related intellectual property rights, has launched decisive measures to protect its creative and industrial assets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113797570/en/ Photo courtesy of White s.r.o. “Vehicle sealed in Chongqing as part of actions undertaken to protect VELOCIFERO’s intellectual property rights.” The matter originated in June 2026 when, according to the company’s complaint, computers were removed from the technical office of Taizhou Siweiluo, the company appointed to manufacture VELOCIFERO products. White s.r.o. subsequently became aware

LangChain Raises $300M to Enable Every Company to Own Their Intelligence13.11.2026 16:53:00 CET | Press release

CapitalG leads Series C funding round at a $3B valuation to advance LangChain's agent engineering platform LangChain today announced it has raised $300 million in new funding at a $3 billion valuation, bringing total funding to date to $460 million. The round was led by existing investor CapitalG, with significant participation from new investors GIC and DFJ Growth and existing investors IVP and Sapphire Ventures. LangChain is advancing its mission to help every company own its intelligence. As agents transform the economy, companies are building domain-specific agents differentiated by their knowledge, data, and user experience. These agents will power new products and transform internal company operations, creating lasting competitive advantages for the companies that control them. "Agents are going to transform how companies operate and the products they deliver. The companies that control these systems will build lasting competitive advantages," said Harrison Chase, Co-Founder and

Kinaxis Named a Leader in Five 2026 IDC MarketScapes for Worldwide Supply Chain Planning13.11.2026 13:00:00 CET | Press release

Maestro delivers concurrent planning on a single platform across discrete, process, consumer packaged goods and life sciences Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced it has been named a Leader in five 2026 IDC MarketScape vendor assessments for worldwide supply chain planning. The recognition spans the overall market and four industries - discrete industries, process industries, consumer packaged goods and life sciences industries - all served by a single platform, Kinaxis Maestro®, the company's AI-powered supply chain orchestration platform. "Supply chain leaders don't need a better forecast once a month. They need to know what changed this morning, what it means across the business, and what to do about it," said Andrew Bell, Chief Product Officer of Kinaxis. "I believe being named a Leader across five IDC MarketScape vendor assessments, in industries that plan in very different ways, shows that a single concurr

SBC Medical Announces Capital and Business Alliance with NeuroBrain Dynamics to Advance Clinic Profitability Through Medical AI13.11.2026 12:30:00 CET | Press release

Companies to co-develop six medical AI solutions targeting revenue expansion and cost reduction; SBC Medical secures priority sales rights in Japan and South Korea and targets B2B expansion across Asia SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced a strategic capital and business alliance agreement with NeuroBrain Dynamics Inc. (“NBD”), a Taipei-based company dedicated to enterprise generative AI solutions. As part of the agreement executed on November 13, 2026, SBC Medical has made a minority equity investment in NBD. Through this alliance, SBC Medical plans to introduce two complementary suites of generative AI solutions across its network of 287 clinics in Japan and overseas*: “revenue-growth AI,” to elevate average revenue per visit and customer retention through personalized customer guidance, and “cost-reduction AI,

SBC Medical Group Holdings Reports Third Quarter 2026 Financial Results13.11.2026 12:30:00 CET | Press release

Revenue Up 35%, Net Income Attributable to SBC Medical Up 22%, and Adjusted EBITDA1 Up 66% Year-over-Year; Net Income Margin of 27% and Adjusted EBITDA Margin of 47% — Previously Announced Service Fee Revisions and New Clinic Openings Contribute to Revenue Growth and Operating Margin Improvement SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the third quarter of fiscal year 2026 (the three months ended September 30, 2026) and the three cumulative quarters of fiscal year 2026 (the nine months ended September 30, 2026). Third Quarter 2026 Financial Highlights Total revenues were $59 million, up 35% year-over-year. Income from operations was $26 million, up 66% year-over-year, with an operating margin of 45%. Net income attributable to SBC Medi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye